Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)
Germany · Delayed Price · Currency is EUR 0.3420
+0.0020 (0.59%)
At close: Jan 30, 2026
FRA:FDY Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 711.63 | 709.4 | 850.73 | 1,031 | 1,140 | 832.47 |
Other Revenue | - | - | - | - | 0.5 | 1.34 |
| 711.63 | 709.4 | 850.73 | 1,031 | 1,140 | 833.8 | |
Revenue Growth (YoY) | 2.89% | -16.61% | -17.50% | -9.57% | 36.76% | -18.99% |
Cost of Revenue | 73.43 | 63.46 | 74.08 | 86.29 | 81.02 | 66.09 |
Gross Profit | 638.2 | 645.95 | 776.66 | 944.87 | 1,059 | 767.72 |
Selling, General & Admin | 439.74 | 341.04 | 426.45 | 599.5 | 660.26 | 475.71 |
Research & Development | 322.45 | 314.16 | 243.76 | 226.85 | 224.39 | 139.27 |
Other Operating Expenses | 17.51 | 7.44 | 5.39 | 6.84 | 6.15 | 4.08 |
Operating Expenses | 743.26 | 653.7 | 699.5 | 830.78 | 896.57 | 624.97 |
Operating Income | -105.06 | -7.75 | 77.15 | 114.09 | 162.72 | 142.74 |
Interest Expense | -0.69 | -0.59 | -3.07 | -1.54 | -1.06 | -5.6 |
Interest & Investment Income | 3.22 | 5.55 | 7.97 | 11.29 | 25.89 | 23.36 |
Currency Exchange Gain (Loss) | 0.15 | 0.15 | -1.08 | -0.83 | 0.14 | -0.3 |
Other Non Operating Income (Expenses) | -0.31 | -0.05 | -0.42 | -0.14 | 6.21 | -6.7 |
EBT Excluding Unusual Items | -102.69 | -2.69 | 80.56 | 122.88 | 193.91 | 153.5 |
Gain (Loss) on Sale of Investments | -10.41 | -10.41 | -4.35 | -1.28 | - | - |
Gain (Loss) on Sale of Assets | 0.1 | 0.03 | 0.3 | 1.92 | 1.78 | 4.6 |
Asset Writedown | -3.99 | -3.93 | -5 | -1.83 | -2.15 | -0.83 |
Other Unusual Items | 22.38 | 22.46 | 26.02 | 10.61 | 22.38 | 19.43 |
Pretax Income | -94.61 | 5.46 | 97.53 | 132.29 | 215.92 | 176.7 |
Income Tax Expense | -31.74 | -33.98 | -10.92 | -4.98 | 3.54 | 12.44 |
Earnings From Continuing Operations | -62.87 | 39.43 | 108.45 | 137.27 | 212.38 | 164.26 |
Minority Interest in Earnings | 0.2 | 0.3 | 0.18 | 0.72 | 0.92 | 0.4 |
Net Income | -62.67 | 39.73 | 108.63 | 138 | 213.3 | 164.66 |
Net Income to Common | -62.67 | 39.73 | 108.63 | 138 | 213.3 | 164.66 |
Net Income Growth | - | -63.42% | -21.28% | -35.30% | 29.54% | -27.58% |
Shares Outstanding (Basic) | 824 | 1,037 | 1,034 | 1,030 | 1,041 | 989 |
Shares Outstanding (Diluted) | 824 | 1,037 | 1,034 | 1,031 | 1,045 | 989 |
Shares Change (YoY) | -24.84% | 0.23% | 0.29% | -1.29% | 5.59% | 7.20% |
EPS (Basic) | -0.08 | 0.04 | 0.11 | 0.13 | 0.20 | 0.17 |
EPS (Diluted) | -0.08 | 0.04 | 0.11 | 0.13 | 0.20 | 0.17 |
EPS Growth | - | -63.51% | -19.19% | -35.00% | 20.17% | -32.44% |
Free Cash Flow | 99.3 | -59.18 | -27.95 | 77.96 | 148.78 | 70.59 |
Free Cash Flow Per Share | 0.12 | -0.06 | -0.03 | 0.08 | 0.14 | 0.07 |
Dividend Per Share | 0.030 | 0.050 | 0.070 | 0.070 | 0.070 | 0.050 |
Dividend Growth | -66.67% | -28.57% | - | - | 40.00% | -28.57% |
Gross Margin | 89.68% | 91.05% | 91.29% | 91.63% | 92.90% | 92.07% |
Operating Margin | -14.76% | -1.09% | 9.07% | 11.06% | 14.27% | 17.12% |
Profit Margin | -8.81% | 5.60% | 12.77% | 13.38% | 18.70% | 19.75% |
Free Cash Flow Margin | 13.95% | -8.34% | -3.29% | 7.56% | 13.05% | 8.47% |
EBITDA | -50.38 | 45.74 | 129.05 | 186.92 | 216.5 | 191.62 |
EBITDA Margin | -7.08% | 6.45% | 15.17% | 18.13% | 18.99% | 22.98% |
D&A For EBITDA | 54.68 | 53.49 | 51.89 | 72.83 | 53.78 | 48.88 |
EBIT | -105.06 | -7.75 | 77.15 | 114.09 | 162.72 | 142.74 |
EBIT Margin | -14.76% | -1.09% | 9.07% | 11.06% | 14.27% | 17.12% |
Effective Tax Rate | - | - | - | - | 1.64% | 7.04% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.